Intriguingly, Tian et al. [33] also found that among EGFR-TKI-resistant NSCLC patients, those who received immunochemotherapy following TKI failure had a better survival than those who had also received other treatments before immunochemotherapy (median PFS: 7.2 vs. 3.4 months, P < 0.0001; median OS: 15.1 vs. 8.4 months, P < 0.0001). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.